Symbol="KZR"
AssetType="Common Stock"
Name="Kezar Life Sciences Inc"
Description="Kezar Life Sciences, Inc., a clinical-stage biotechnology company, is dedicated to the discovery and development of new small molecule therapies to address the unmet needs in immune-mediated diseases and cancer in the United States. The company is headquartered in South San Francisco, California."
CIK="1645666"
Exchange="NASDAQ"
Currency="USD"
Country="USA"
Sector="LIFE SCIENCES"
Industry="PHARMACEUTICAL PREPARATIONS"
Address="4000 SHORELINE COURT, SUITE 300, SOUTH SAN FRANCISCO, CA, US"
FiscalYearEnd="December"
LatestQuarter="2023-03-31"
MarketCapitalization="174501000"
EBITDA="-78943000"
PERatio="None"
PEGRatio="None"
BookValue="3.565"
DividendPerShare="0"
DividendYield="0"
EPS="-1.09"
RevenuePerShareTTM="0"
ProfitMargin="0"
OperatingMarginTTM="0"
ReturnOnAssetsTTM="-0.186"
ReturnOnEquityTTM="-0.307"
RevenueTTM="0"
GrossProfitTTM="0"
DilutedEPSTTM="-1.09"
QuarterlyEarningsGrowthYOY="0"
QuarterlyRevenueGrowthYOY="0"
AnalystTargetPrice="15.5"
TrailingPE="-"
ForwardPE="-"
PriceToSalesRatioTTM="-"
PriceToBookRatio="1.688"
EVToRevenue="-"
EVToEBITDA="-3.262"
Beta="0.129"
num_52WeekHigh="10.81"
num_52WeekLow="2.25"
num_50DayMovingAverage="2.609"
num_200DayMovingAverage="5.06"
SharesOutstanding="72407000"
DividendDate="None"
ExDividendDate="None"
symbol="KZR"
open="2.42"
high="2.43"
low="2.27"
price="2.28"
volume="390285.00"
latest_trading_day="2023-07-24"
previous_close="2.41"
change="-0.13"
change_percent="-5.3942%"
aroon_positive_momentum_days="0"
aroon_negative_momentum_days="100"
trend_strength="Absent or Weak Trend"
buying_signal="High Volatility / Hold Signal"
volume_analysis="Target Volume"
value_analysis="Expected Range"
Aroon_change="FALSE"
Aroon_momentum="0"
Volume_recent_avg="998352"
Change_recent_avg="-0.04"
Delta_recent_avg="0.22"
Variance_recent_avg="0.11"
Change_ratio_recent_avg="-1.2"
RSI_change="FALSE"
ADX_change="FALSE"
Aroon_signal="negative"
Aroon_change="FALSE"
Aroon_momentum_positive="0"
Aroon_momentum_negative="100"
image_negative_thumbnail_id_1="1109"
image_negative_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Negative_Landscape_0142.jpeg"
image_negative_thumbnail_id_2="1116"
image_negative_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Negative_Landscape_0149.jpeg"
image_neutral_thumbnail_id_1="540"
image_neutral_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0059.jpeg"
image_neutral_thumbnail_id_2="594"
image_neutral_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0005.jpeg"
image_positive_thumbnail_id_1="630"
image_positive_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0078.jpeg"
image_positive_thumbnail_id_2="666"
image_positive_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0042.jpeg"
image_professor_thumbnail_id_1="1178"
image_professor_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0012.jpeg"
image_professor_thumbnail_id_2="1169"
image_professor_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0003.jpeg"
